Mechanism of Action

Ticagrelor is an oral antiplatelet agent that reversibly inhibits the P2Y12 ADP receptor on platelets. This inhibition prevents platelet activation and aggregation, thereby reducing the risk of thrombotic cardiovascular events in patients with acute coronary syndrome and those undergoing percutaneous coronary intervention.

Indication

Indicated for the prevention of atherothrombotic events in patients with acute coronary syndrome (ACS) or a history of myocardial infarction.